David M. Layton

London, ENG, United Kingdom

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 33 publications

Acanthocytosis Contributes to the Diagnosis of the McLeod Syndrome.

Acanthocytosis Contributes to the Diagnosis of the McLeod Syndrome.

Journal: American journal of hematology

Published: June 20, 2025

Long-term efficacy and safety of mitapivat in non-transfusion-dependent α- or β-thalassaemia: An open-label phase 2 study.

Long-term efficacy and safety of mitapivat in non-transfusion-dependent α- or β-thalassaemia: An open-label phase 2 study.

Journal: British journal of haematology

Published: October 10, 2024

Putting unstable hemoglobins on the map of London.

Putting unstable hemoglobins on the map of London.

Journal: American journal of hematology

Published: June 30, 2023

The Pyruvate Kinase Deficiency Global Longitudinal (Peak) Registry: rationale and study design.

The Pyruvate Kinase Deficiency Global Longitudinal (Peak) Registry: rationale and study design.

Journal: BMJ open

Published: March 23, 2023

Bone mineral density in adult patients with pyruvate kinase deficiency on long-term mitapivat treatment.

Bone mineral density in adult patients with pyruvate kinase deficiency on long-term mitapivat treatment.

Journal: Haematologica

Published: February 03, 2023

Early-onset reduced bone mineral density in patients with pyruvate kinase deficiency.

Early-onset reduced bone mineral density in patients with pyruvate kinase deficiency.

Journal: American journal of hematology

Published: September 09, 2022

Safety and efficacy of mitapivat, an oral pyruvate kinase activator, in adults with non-transfusion dependent α-thalassaemia or β-thalassaemia: an open-label, multicentre, phase 2 study.

Safety and efficacy of mitapivat, an oral pyruvate kinase activator, in adults with non-transfusion dependent α-thalassaemia or β-thalassaemia: an open-label, multicentre, phase 2 study.

Journal: Lancet (London, England)

Published: May 20, 2022

Mitapivat versus Placebo for Pyruvate Kinase Deficiency.

Mitapivat versus Placebo for Pyruvate Kinase Deficiency.

Journal: The New England journal of medicine

Published: April 13, 2022

Voxelotor in sickle cell disease.

Voxelotor in sickle cell disease.

Journal: American journal of hematology

Published: March 24, 2022

Whole genome sequences discriminate hereditary hemorrhagic telangiectasia phenotypes by non-HHT deleterious DNA variation.

Whole genome sequences discriminate hereditary hemorrhagic telangiectasia phenotypes by non-HHT deleterious DNA variation.

Journal: Blood advances

Published: January 24, 2022

Peripheral blood features of iron overload in post-splenectomy, type I congenital dyserythropoietic anemia.

Peripheral blood features of iron overload in post-splenectomy, type I congenital dyserythropoietic anemia.

Journal: American journal of hematology

Published: August 12, 2021

Sickle cell disease patients in two London trusts: Genotyping including RH variants.

Sickle cell disease patients in two London trusts: Genotyping including RH variants.

Journal: Transfusion medicine (Oxford, England)

Published: May 25, 2021

Showing 1-12 of 33

Last Updated: 09/26/2026